A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder

Current Psychiatry Reports

Volumn 12, Issue 5, 2010, Pages 471-477

  Stein, Dan J ^a   Baldwin, David S ^a   Bandelow, Borwin ^a   Blanco, Carlos ^a   Fontenelle, Leonardo F ^a   Lee, Sing ^a   Matsunaga, Hisato ^a   Osser, David ^a   Stein, Murray B ^a   Van Ameringen, Michael ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Pharmacotherapy; Social anxiety disorder

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; ESCITALOPRAM; ETIRACETAM; FLUOXETINE; FLUVOXAMINE; GABAPENTIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PAROXETINE; PLACEBO; PREGABALIN; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ANTICHOLINERGIC SYNDROME; ANXIETY DISORDER; ARTICLE; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HUMAN; MAINTENANCE THERAPY; OPTIMAL DRUG DOSE; PSYCHOPHARMACOTHERAPY; SEXUAL DYSFUNCTION; SOCIAL PHOBIA; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; ANTI-ANXIETY AGENTS; HUMANS; PHOBIC DISORDERS; TREATMENT OUTCOME;

EID: 77958175614     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-010-0140-8     Document Type: Article

References (59)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, edn 4. Washington, DC: American Psychiatric Association; 1994.
2. DJ Stein AM Ruscio S Lee, et al. 2010 Subtyping social anxiety disorder in developed and developing countries Depress Anxiety 27 390 403 10.1002/da.20639 20037919
3. MB Stein DJ Stein 2008 Social anxiety disorder Lancet 371 1115 1125 10.1016/S0140-6736(08)60488-2 18374843 (Pubitemid 351418007)
4. Beard C, Moitra E, Weisberg RB, et al.: Characteristics and predictors of social phobia course in a longitudinal study of primary-care patients. Depress Anxiety 2010 Feb 23 (Epub ahead of print).
5. L Fehm A Pelissolo T Furmark, et al. 2005 Size and burden of social phobia in Europe Eur Neuropsychopharmacol 15 453 462 1:CAS:528: DC%2BD2MXlvFarsbg%3D 10.1016/j.euroneuro.2005.04.002 15921898 (Pubitemid 40949552)
6. C Blanco MS Raza FR Schneier, et al. 2003 The evidence-based pharmacological treatment of social anxiety disorder Int J Neuropsychopharmacol 6 427 442 1:CAS:528:DC%2BD3sXpsFOnurY%3D 10.1017/S1461145703003791 14609440 (Pubitemid 38146264)
7. DJ Stein JC Ipser AJ Balkom 2004 Pharmacotherapy for social anxiety disorder Cochrane Database Syst Rev 4 CD001206 15495010
8. JC Ipser P Carey Y Dhansay, et al. 2006 Pharmacotherapy augmentation strategies in treatment-resistant anxiety disorders Cochrane Database Syst Rev 4 CD005473 17054260
9. B Bandelow J Zohar E Hollander, et al. 2008 World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision World J Biol Psychiatry 9 248 312 10.1080/15622970802465807 18949648 This paper provides a systematic review of the literature on the pharmacotherapy of anxiety disorders, as well as guidelines for clinicians
10. DS Baldwin IM Anderson DJ Nutt, et al. 2005 Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology J Psychopharmacol 19 567 596 1:CAS:528:DC%2BD2MXht1Kru77N 10.1177/0269881105059253 16272179 (Pubitemid 41578819)
11. RP Swinson MM Antony PB Bleau, et al. 2006 Clinical practice guidelines: management of anxiety disorders Can J Psychiatry 51 Suppl 2 1 92
12. DJ Stein S Kasper H Matsunaga, et al. 2001 Pharmacotherapy of social anxiety disorder: an algorithm for primary care-2001 Prim Care Psychiatry 7 107 110 10.1185/135525701317094368 (Pubitemid 33039999)
13. Stein DJ, Lerer B, Stahl S: Evidence-Based Psychopharmacology. Cambridge, United Kingdom: Cambridge University Press; 2005.
14. Fawcett J, Stein DJ, Jobson KO: Textbook of Treatment Algorithms in Psychopharmacology. Chichester, United Kingdom: John Wiley & Sons; 1999.
15. AJ Rush 2001 Clinical practice guidelines: good news, bad news, or no news? Arch Gen Psychiatry 50 483 490
16. AM Letamendi DA Chavira MB Stein 2009 Issues in the assessment of social phobia: a review Isr J Psychiatry Relat Sci 46 13 24 19728569
17. JE Muller L Koen S Seedat, et al. 2005 Social anxiety disorder: current treatment recommendations CNS Drugs 19 377 391 1:CAS:528:DC%2BD2MXms1aqtbo%3D 10.2165/00023210-200519050-00002 15907150 (Pubitemid 41124013)
18. C Blanco RG Heimberg FR Schneier, et al. 2010 A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder Arch Gen Psychiatry 67 286 295 1:CAS:528: DC%2BC3cXktlSrtbc%3D 10.1001/archgenpsychiatry.2010.11 20194829
19. JS Singh DA Hope 2009 Cognitive-behavioral approaches to the treatment of social anxiety disorder Isr J Psychiatry Relat Sci 46 62 69 19728574
20. CA Hitchcock DA Chavira MB Stein 2009 Recent findings in social phobia among children and adolescents Isr J Psychiatry Relat Sci 46 34 44 19728571
21. Ipser JC, Stein DJ, Hawkridge S, et al.: Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 2009, 3:CD005170.
22. DN Osser JA Renner Jr 1999 Bayog R: Algorithms for the pharmacotherapy of anxiety disorders in patients with chemical abuse and dependence Psychiatr Ann 29 285 301
23. M Tuccori A Testi L Antonioli, et al. 2009 Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/ noradrenergic antidepressants during pregnancy: a review Clin Ther 31 1426 1453 10.1016/j.clinthera.2009.07.009 19698902
24. KA Kobak JH Greist JW Jefferson DJ Katzelnick 2002 Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study J Clin Psychopharmacol 22 257 262 1:CAS:528:DC%2BD38XksFCkurs%3D 10.1097/00004714-200206000-00005 12006895 (Pubitemid 34546840)
25. JRT Davidson EB Foa JD Huppert, et al. 2004 Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia Arch Gen Psychiatry 61 1005 1013 1:CAS:528:DC%2BD2cXptFOht7w%3D 10.1001/archpsyc.61.10. 1005 15466674 (Pubitemid 39336534)
26. MR Liebowitz F Schneier R Campeas, et al. 1992 Phenelzine vs atenolol in social phobia: a placebo-controlled comparison Arch Gen Psychiatry 49 290 300 1:STN:280:DyaK383hsFSltw%3D%3D 1558463
27. JRT Davidson N Potts E Richichi, et al. 1993 Treatment of social phobia with clonazepam and placebo J Clin Psychopharmacol 13 423 428 1:STN:280:DyaK2c7msFaiuw%3D%3D 10.1097/00004714-199312000-00008 8120156
28. DJ Stein MB Stein W Goodwin B Hunter 2001 The selective serotonin reuptake inhibitor paroxetine is effective in more generalized and less generalized social anxiety disorder Psychopharmacology (Berl) 158 267 272 1:CAS:528:DC%2BD3MXpt1ClsrY%3D 10.1007/s002130100880 (Pubitemid 33071164)
29. M Lader K Stender V Bürger R Nil 2004 The efficacy and tolerability of escitalopram in the short- and long-term treatment of social anxiety disorder: a randomised, double-blind, placebo-controlled, fixed-dose study Depress Anxiety 19 241 248 1:CAS:528:DC%2BD2cXnt1elsrk%3D 10.1002/da.20014 15274173 (Pubitemid 39014144)
30. DJ Stein A Cameron R Amrein SA Montgomery 2002 Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder Int Clin Psychopharmacol 17 161 170 1:STN:280:DC%2BD38znvFahuw%3D%3D 10.1097/00004850-200207000-00002 12131599
31. D Nutt SA Montgomery 1996 Moclobemide in the treatment of social phobia Int Clin Psychopharmacol 11S 77 82 10.1097/00004850-199606003-00013
32. LF Allsopp GL Cooper PH Poole 1984 Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice Curr Med Res Opin 9 64 70 1:STN:280:DyaL2c3gs12isQ%3D%3D 6373161
33. G Beaumont 1977 A large open multicenter trial of clomipramine (Anafranil) in the management of phobic disorders J Int Med Res 5 116 123 598600
34. KM Connor JRT Davidson NLS Potts, et al. 1998 Discontinuation of clonazepam in the treatment of social phobia J Clin Psychopharmacol 18 373 378 1:CAS:528:DyaK1cXmvFWktLw%3D 10.1097/00004714-199810000-00004 9790154 (Pubitemid 28462626)
35. AC Pande JR Davidson JW Jefferson, et al. 1999 Treatment of social phobia with gabapentin: a placebo-controlled study J Clin Psychopharmacol 19 341 348 1:CAS:528:DyaK1MXlt1aisLs%3D 10.1097/00004714-199908000-00010 10440462 (Pubitemid 29344848)
36. AC Pande DE Feltner JW Jefferson, et al. 2004 Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study J Clin Psychopharmacol 24 141 149 1:CAS:528: DC%2BD2cXjslSitrY%3D 10.1097/01.jcp.0000117423.05703.e7 15206660 (Pubitemid 38380837)
37. MB Stein LN Ravindran NM Simon, et al. 2010 Levetiracetam in generalized social anxiety disorder: a double-blind, randomized controlled trial J Clin Psychiatry 71 627 631 1:CAS:528:DC%2BC3cXotVWlurg%3D 10.4088/JCP.08m04949gre 20021997
38. DJ Stein H Westenberg MR Liebowitz 2002 Social anxiety disorder and generalized anxiety disorder: serotonergic and dopaminergic neurocircuitry J Clin Psychiatry 63 Suppl 6 12 19 12027115
39. SD Barnett ML Kramer CD Casat, et al. 2002 Efficacy of olanzapine in social anxiety disorder: a pilot study J Psychopharmacol 16 365 368 1:CAS:528:DC%2BD3sXlvFaruw%3D%3D 10.1177/026988110201600412 12503837
40. S Vaishnavi S Alamy W Zhang, et al. 2007 Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study Prog Neuropsychopharmacol Biol Psychiatry 31 1464 1469 1:CAS:528:DC%2BD2sXpvF2rtrs%3D 10.1016/j.pnpbp. 2007.06.027 17698275 (Pubitemid 47302561)
41. S Pallanti L Quercioli A Rossi A Pazzagli 1999 The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation J Clin Psychiatry 60 819 823 1:CAS:528:DC%2BD3cXos1Gqtg%3D%3D 10.4088/JCP.v60n1203 10665627
42. KM Connor JRT Davidson LE Churchill, et al. 2000 Psychometric properties of the Social Phobia Inventory (SPIN): new self-rating scale Br J Psychiatry 176 379 386 1:STN:280:DC%2BD3c3oslahtg%3D%3D 10.1192/bjp.176.4.379 10827888
43. Liebowitz MR: Social phobia. In Modern Problems of Pharmacopsychiatry. Edited by Ban TA, Pichot P, Poldinger W. Basel, Switzerland: Karger; 1987.
44. B Bandelow DS Baldwin OT Dolberg, et al. 2006 What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? J Clin Psychiatry 67 1428 1434 10.4088/JCP.v67n0914 17017830
45. S Seedat MB Stein 2004 Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder J Clin Psychiatry 65 244 248 1:CAS:528:DC%2BD2cXivVWjsbY%3D 15003080
46. S Pallanti L Quercioli 2006 Resistant social anxiety disorder response to escitalopram Clin Pract Epidemiol Ment Health 2 35 10.1186/1745-0179-2-35 17166264 (Pubitemid 46195844)
47. GJH van der Linden DJ Stein AJLM van Balkom 2000 The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials Int Clin Psychopharmacol 15 Suppl 2 15 24
48. DJ Stein MB Stein CD Pitts, et al. 2002 Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials J Clin Psychiatry 63 152 155 1:CAS:528:DC%2BD38Xit1ait70%3D 11874217
49. M Van Ameringen C Allgulander B Bandelow, et al. 2003 WCA recommendations for the long-term treatment of social phobia CNS Spectr 8 40 52 14767397 (Pubitemid 38419780)
50. M Versiani R Amrein SA Montgomery 1997 Social phobia: long-term treatment outcome and prediction of response-a moclobemide study Int Clin Psychopharmacol 12 239 254 1:STN:280:DyaK1c7islejtA%3D%3D 10.1097/00004850-199709000-00001 9466158
51. C Blanco RG Heimberg FR Schneier, et al. 2010 A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder Arch Gen Psychiatry 67 286 295 1:CAS:528: DC%2BC3cXktlSrtbc%3D 10.1001/archgenpsychiatry.2010.11 20194829
52. M van Ameringen C Mancini C Wilson 1996 Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia J Affect Disord 39 115 121 10.1016/0165-0327(96)00030-4 8827420 (Pubitemid 26232803)
53. IM van Vliet JA den Boer HG Westenberg, et al. 1997 Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study J Clin Psychiatry 58 164 168 9164427
54. S Seedat MB Stein 2004 Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder J Clin Psychiatry 65 244 248 1:CAS:528:DC%2BD2cXivVWjsbY%3D 15003080
55. NM Simon EA Hoge D Fischmann, et al. 2006 An open-label trial of risperidone augmentation for refractory anxiety disorders J Clin Psychiatry 67 381 385 1:CAS:528:DC%2BD28Xkt1KmsLw%3D 10.4088/JCP.v67n0307 16649823
56. JJ Worthington III G Kinrys LE Wygant, et al. 2005 Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients Int Clin Psychopharmacol 20 9 11 10.1097/00004850-200501000- 00002 15602109 (Pubitemid 40105542)
57. JE Kelsey 1995 Venlafaxine in social phobia Psychopharmacol Bull 31 767 771 1:CAS:528:DyaK28XitlKrtrw%3D 8851651
58. AC Altamura R Pioli M Vitto, et al. 1999 Venlafaxine in social phobia: a study in selective serotonin reuptake non-responders Int Clin Psychopharmacol 14 239 245 1:STN:280:DyaK1Mzps1eqsQ%3D%3D 10.1097/00004850-199907000-00006 10468317 (Pubitemid 29358991)
59. TF Aarre 2003 Phenelzine efficacy in refractory social anxiety disorder: a case series Nord J Psychiatry 57 313 315 10.1080/08039480310002110 12888407 (Pubitemid 37080815)